Core Scientific, Inc. current report, 10 November 2023

全文

Core Scientific, Inc. — Form 8-K Summary

Business context and reporting period

Core Scientific, Inc. filed this Current Report on November 13, 2023, reporting an event dated November 10, 2023. The company and certain affiliates remain debtors-in-possession in Chapter 11 proceedings initiated on December 21, 2022, in the U.S. Bankruptcy Court for the Southern District of Texas.

The filing announces the submission of a Third Amended Joint Chapter 11 Plan of Reorganization on November 10, 2023. A related Third Amended Disclosure Statement was filed on November 13, 2023.

Financial metrics and liquidity

  • This Form 8-K does not provide revenue, profit, cash flow, margin, debt-balance, or liquidity figures.
  • The company identifies liquidity risks associated with the Chapter 11 cases, including potential adverse effects on operations, increased professional costs, debt acceleration, and the finalization and funding conditions of a replacement debtor-in-possession facility.
  • The company’s common stock and warrants trade exclusively on the OTC Pink Marketplace under the symbols CORZQ and CRZWQ, respectively, since January 3, 2023.

Material changes and restructuring developments

  • The Third Amended Plan follows prior plans filed in June, August, and September 2023 and an October 30, 2023 agreement in principle with an ad hoc group of secured convertible noteholders and the official equity committee.
  • The proposed restructuring terms are intended to be reflected in the Third Amended Plan and related restructuring documentation.
  • As of the filing date, the company had agreements in principle regarding material restructuring terms and plan support with certain, but not all, key stakeholders. Discussions with remaining stakeholders were continuing.
  • The company expects a restructuring support agreement to address the restructuring transactions, but the filing does not confirm that a final agreement had been executed.

Outlook, risks, contingencies, and unusual items

  • The Third Amended Disclosure Statement had been submitted for Bankruptcy Court approval but had not been approved as of the filing date.
  • Neither the filing of the Third Amended Plan and Disclosure Statement nor the Form 8-K constituted solicitation of votes. Solicitation may begin only after Bankruptcy Court approval of the disclosure statement and in accordance with applicable law.
  • The plan and disclosure statement remain subject to amendment, supplementation, third-party actions, and Bankruptcy Court decisions. There is no assurance that the plan will be approved, that the restructuring will be consummated, or that the company will emerge from Chapter 11.
  • Key risks include failure to obtain court approvals, failure to execute or satisfy conditions to debtor-in-possession financing, inability to implement a restructuring, adverse effects of the bankruptcy cases on liquidity and operations, extended proceedings, increased costs, debt acceleration, and OTC trading volatility.
  • The company states that achieving significant cash flows from operations and successfully emerging from Chapter 11 remain subject to substantial uncertainty.

Important facts for investors to verify

  1. Whether the Bankruptcy Court approved the Third Amended Disclosure Statement and subsequently confirmed the Third Amended Plan.
  2. Whether the company executed a restructuring support agreement with all material stakeholder groups.
  3. The final treatment of secured creditors, unsecured creditors, existing equity holders, and warrants under the confirmed plan.
  4. The status, size, terms, and funding conditions of any replacement debtor-in-possession facility.
  5. The company’s current cash position, operating cash flows, debt obligations, and professional fees, which are not provided in this filing.
  6. Whether the company ultimately emerges from Chapter 11 and the resulting capitalization and trading arrangements.